Antidepressants and Psychiatric Medications in Japan

Antidepressants in Japan are widely available by prescription, but the psychiatric drug picture has sharp edges that surprise newcomers.¹² Most major SSRIs, SNRIs, and atypical antipsychotics are approved, while amphetamine-class ADHD drugs are banned outright and stimulant prescribing is tightly controlled.³¹

Confirm current details with official sources

Procedures, fees, and requirements can change. Confirm current details at the Ministry of Health, Labour and Welfare site and the Narcotics Control Department guidance. This article is general information, not medical advice; for your specific medication, consult a Japan-licensed physician or pharmacist.

Overview

Japan regulates psychiatric drugs nationally through the Ministry of Health, Labour and Welfare (MHLW) and the Pharmaceuticals and Medical Devices Agency (PMDA) for approvals, plus the Narcotics Control Department (NCD) for controlled-substance categories.³²¹ Approval and ban status is uniform nationwide; no ward or municipal variation applies.³²

Access varies by provider, not by region. Any substitution decision sits with the individual Japan-licensed psychiatrist who examines you, and ADHD-stimulant prescribing needs a registered specialist.³ This guide maps the classes, the bans, and the pre-arrival steps; it does not recommend any specific drug or switch.

Term	Reading	Gloss
精神科	seishinka	psychiatry
心療内科	shinryou naika	psychosomatic medicine
処方箋	shohousen	prescription
薬局	yakkyoku	dispensing pharmacy
薬監証明	yakkan shoumei	Medication Import Certificate, legacy name
輸入確認書	yunyu kakunin-sho	Import Confirmation, current official name

What this guide covers and what it does not

This guide covers which antidepressant and related psychiatric classes are available by prescription in Japan, which ADHD and related drugs are restricted or banned, and what a patient on a banned drug does before arrival.³²¹ It follows the NCD category system and the MHLW personal-use import rules.³²

It does not give treatment advice. It states general availability rules and points you to a Japan-licensed psychiatrist or pharmacist for anything about your own regimen.³ The PMDA List of Approved Products, covering new-drug approvals from April 2004 to February 2026, is the authority for whether a specific drug is approved in Japan.¹

Antidepressants available in Japan

Antidepressants in Japan are prescription-only and flow through the standard prescription system: a doctor writes a 処方箋 (shohousen, "prescription") and you fill it at a dispensing pharmacy.² The PMDA List of Approved Products is the check tool for any specific product, covering approvals from April 2004 to February 2026 (as of 2026-02; confirm current approval status with PMDA).¹

SSRIs

Most major SSRIs are approved and available by prescription in Japan, including sertraline, escitalopram, paroxetine, and fluvoxamine.¹ These are established approvals rather than recent additions, so they do not appear as new entries in the recent-approvals list; confirm the exact product with your psychiatrist and the PMDA product search.¹

SSRIs are never over the counter. As prescription drugs, they travel without an Import Confirmation only up to a 1-month supply; anything above that needs the certificate received before departure.²

SNRIs and other antidepressants

The SNRIs duloxetine, venlafaxine, and milnacipran are approved and available by prescription in Japan.¹⁴ PMDA review-report records include Cymbalta (duloxetine hydrochloride) approval material, which confirms duloxetine's place in the approved set.⁴

Like SSRIs, SNRIs are prescription-only under the same 1-month personal-import allowance as other prescription drugs.² If you carry more than a 1-month supply into Japan, file for Import Confirmation before you leave home.²

Antipsychotics, anxiolytics, and sleep-related prescribing norms

Atypical antipsychotics

Most major atypical antipsychotics are approved and available by prescription in Japan.¹ Confirm the exact product with your psychiatrist against the PMDA product search, since brand lineups differ between countries even when the class looks familiar.¹

Atypical antipsychotics are prescription-only.² The same prescription-to-pharmacy path and 1-month import allowance apply as for antidepressants.²

Benzodiazepines and prescribing caution

Benzodiazepine-class anxiolytics and hypnotics are prescription-only in Japan, and several sit inside the NCD psychotropic framework.³ NCD names alprazolam, clonazepam, and diazepam among its psychotropic examples, alongside the sleep aid zolpidem.³

International observers have described benzodiazepine prescribing in Japan as freer than US practice, with an overprescription concern attached to that pattern. Take this as context about the local prescribing culture, not as a rule about your own prescription; only your psychiatrist sets your regimen.

Match your psychotropic quantity to the right paperwork

Psychotropics at or below the NCD table amount, excluding injection form, need neither a doctor certificate nor authority permission under the Narcotics and Psychotropics Control Law.³ Above the table amount, or in injection form, you need a doctor-written certificate identifying the disease, the necessity of the drug, the drug names, and the quantities prescribed.³ Where psychotropic imports exceed a 1-month supply, MHLW also directs applicants to contact yakkan@mhlw.go.jp.³

ADHD stimulants: restrictions and bans

What is restricted: Concerta and methylphenidate

Methylphenidate, including dexmethylphenidate, sits in the NCD psychotropic group that needs no advance NCD permission at or below the table amount.³ Concerta, the osmotic-release form of methylphenidate, is available in Japan, but prescribing is tightly controlled through a registered specialist physician and specific dosage and distribution controls.

Methylphenidate comes only at specific dosages in Japan. When you carry it across the border, the exact strength on the prescription must match the NCD medical-certificate and package-photo requirements.³

What is banned: amphetamine-class drugs

Adderall cannot be brought into Japan.³ Its active ingredient amphetamine is controlled as stimulants under the Stimulants Control Act, and NCD states it cannot be imported even for treatment purposes.³

Do not pack Adderall for Japan under any circumstance

No individual traveler can import or export medicines containing heroin, opium powder, methamphetamine and amphetamine (INN: dexamphetamine, levamfetamine), or methaqualone, even when prescribed abroad.³ Dexedrine falls under the prohibited amphetamine entry through its dexamphetamine INN listing.³ A foreign prescription, a small quantity, or an honest declaration does not make these products legal.

Vyvanse differs from Adderall in procedure. Lisdexamfetamine, the active ingredient in Vyvanse and equivalents such as Elvanse, is controlled as stimulants raw materials, and NCD states it can be imported or exported with advance permission.³ That permission is a separate NCD application to the Regional Bureau directors, not the general Import Confirmation alone.³

The NCD application uses the NCD import form plus a medical certificate issued within 3 months and package photos showing name and strength.³ The certificate must state your name, current address, the specific reason for the medicine (a bare "personal use" statement is not accepted), the medicine list with doses and strength, the prescribing doctor signature, and the issue date.³

Apply at least 14 days before travel (as of 2026-09-07; confirm current timelines with NCD).³ Tokyo NCD states it accepts no last-minute applications for any reason, even by phone or email contact.³

Medicines under NCD permission must be carried on the person; they cannot be mailed and cannot be entrusted to family or others.³ Show the import and export certificates to the customs officer on entry and exit.³

Modafinil and newer agents

Modafinil is prescription-only and narrowly indicated in Japan. Do not assume that an abroad prescription with a broader indication transfers directly; your Japan-licensed psychiatrist determines the local indication.

Some newer mental-health drugs available abroad are not yet approved in Japan, so approval lag is a real planning factor (as of 2026-02).¹ Check the exact product against the PMDA List of Approved Products and raise anything absent with your psychiatrist early rather than assuming an import path exists.¹

Getting prescribed and continuing treatment

Seeing a psychiatrist and filling the prescription

Continuing or starting psychiatric medication in Japan runs through a Japan-licensed psychiatrist at a 精神科 (seishinka, "psychiatry") or 心療内科 (shinryou naika, "psychosomatic medicine") clinic or hospital department, who writes the prescription you fill at a dispensing pharmacy.² Bring your medication history and, where you have one, your medication record book to the first visit.

Insurance coverage at the pharmacy follows the standard prescription-dispensing path, with a co-pay on the drug cost plus a dispensing fee. The exact share depends on your insurance type, so confirm the mechanism, not a fixed number, with your insurer and pharmacy.

If you take a banned drug abroad: pre-arrival strategy

Start with the active ingredient, not the brand. The NCD controlled-substances list does not include brand names, so check the exact ingredient against the NCD categories with the doctor who prescribed it.³ The diagram below shows the decision path.

For import-permittable categories, apply for Yunyu Kakunin-sho (Import Confirmation) and receive it before leaving home, then show it to the customs officer on arrival.²⁵ Prescription drugs above a 1-month supply need the certificate; embassy guidance advises applying at least 2 weeks before the travel date (as of 2026-05-18; confirm current timing with the Regional Bureau covering your arrival airport).⁵

Start the application early enough to survive review

NCD asks travelers to apply at least 14 days before travel, and Tokyo NCD accepts no last-minute applications.³ Embassy pages give the same 2-week advice for the standard certificate track.⁵ A late start can mean traveling without the medicine.

Categorically banned active ingredients have no certificate path, so the plan must change before travel to a Japan-side substitute decided with a Japan-licensed psychiatrist.³² This article states that rule only; it does not suggest which substitute fits any person. Where a prescription runs out in Japan, the path is a Japan-side clinical consultation, not an automatic certificate renewal.

Item	Detail	As of
NCD narcotics or stimulants-raw-material permission fee	No fee stated on the fetched guidance3	2026-09-07
Yunyu Kakunin-sho application fee	No fee stated on the fetched guidance5	2026-05-18

Neither fetched guidance states an application fee, so budget for clinical costs (psychiatrist visit, pharmacy co-pay) rather than a permit fee. Confirm current fee practice with NCD or the Regional Bureau if a payment page appears after this article's check dates.

Good to know

Check the ingredient, not just the brand, before you pack

The NCD list works in active-ingredient names, and the same brand abroad can mean a different formula in Japan.³ Sit down with the prescribing doctor and map every product to its ingredient, then to the NCD category, before deciding between the standard certificate, the NCD permission, or a Japan-side substitute plan.³

A foreign prescription does not legalize a banned drug

An over-limit supply with only a doctor letter is still short at customs, and a banned active ingredient has no certificate path at all.³² Above-allowance and restricted-category imports need the issued certificate or NCD permission received before departure and shown on request.³²

Line up the psychiatrist before the plane, not after landing

Substitution is a psychiatrist decision, not a self-swap. Embassy guidance points to a 2-week application lead time (as of 2026-05-18), and NCD sets a 14-day floor with no Tokyo exceptions (as of 2026-09-07).⁵³ A patient stable abroad on a banned drug who arrives without a Japan-side plan risks an uncovered gap in treatment.

Recently approved abroad can still mean unapproved in Japan

Newer agents reach the Japanese market later than some home markets. The PMDA List of Approved Products through February 2026 is the check tool (as of 2026-02); anything absent needs a psychiatrist-led plan rather than an import assumption.¹

See also

• What to Bring to a Doctor's Visit
• Booking a Doctor in Japan
• Selecting a Local Clinic as Primary Care
• Psychiatry, Psychology, and Counseling in Japan
• English-Speaking Mental Health Providers
• Crisis Resources in Japan

References

Footnotes

1. Pharmaceuticals and Medical Devices Agency. "List of Approved Products" (English, new drugs April 2004 to February 2026). https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³ ↩¹⁴

2. Ministry of Health, Labour and Welfare. "Information for those who are bringing medicines for personal use into Japan" (English). https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/iyakuhin/kojinyunyu/topics/tp010401-1_00001.html ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³ ↩¹⁴ ↩¹⁵ ↩¹⁶

3. Narcotics Control Department, Ministry of Health, Labour and Welfare. "Application Guidance" (English). https://www.ncd.mhlw.go.jp/en/application2.html ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³ ↩¹⁴ ↩¹⁵ ↩¹⁶ ↩¹⁷ ↩¹⁸ ↩¹⁹ ↩²⁰ ↩²¹ ↩²² ↩²³ ↩²⁴ ↩²⁵ ↩²⁶ ↩²⁷ ↩²⁸ ↩²⁹ ↩³⁰ ↩³¹ ↩³² ↩³³ ↩³⁴ ↩³⁵

4. Pharmaceuticals and Medical Devices Agency. "Review Reports: Drugs" (English). https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0001.html ↩ ↩²

5. Embassy of Japan in the United States. "Bringing Medications into Japan" (English). Updated 2026-05-18. https://www.us.emb-japan.go.jp/itpr_en/bringing-medications-to-japan.html ↩ ↩² ↩³ ↩⁴ ↩⁵